Business Context and Reporting Period
Sana Biotechnology, Inc. filed a Form 8-K dated June 6, 2022, reporting the results of its 2022 annual meeting of stockholders held on that date. The filing concerns corporate governance matters rather than operating or financial results.
Key Financial Metrics
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes Versus Prior Comparable Period
- All four Class I director nominees were elected to three-year terms expiring at the 2025 annual meeting.
- Stockholders ratified Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022.
Guidance, Outlook, Risks, and Unusual Items
The filing provides no management guidance, operating outlook, risk updates, contingencies, or unusual financial items. It identifies Sana as an emerging growth company and states that its common stock trades on The Nasdaq Global Select Market under the symbol SANA.
Important Facts for Investors to Verify
- Director election results, including broker non-votes: Douglas Cole, M.D., 95,399,718 votes for; Steven D. Harr, M.D., 101,290,115; Michelle Seitz, CFA, 101,236,242; and Patrick Y. Yang, Ph.D., 97,206,354.
- Each director nominee received a three-year term expiring at the 2025 annual meeting.
- Ernst & Young LLP appointment ratification: 121,383,541 votes for, 69,855 against, and 18,107 abstentions.
- The filing text does not provide the total shares outstanding, quorum information, or financial condition as of the meeting date.